Cargando…

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

BACKGROUND: The safety and immunogenicity of a vaccine regimen consisting of a 6-plasmid HIV-1 DNA prime (envA, envB, envC, gagB, polB, nefB) boosted by a recombinant adenovirus serotype-5 (rAd5) HIV-1 with matching inserts was evaluated in HIV-seronegative participants from South Africa, United Sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Churchyard, Gavin J., Morgan, Cecilia, Adams, Elizabeth, Hural, John, Graham, Barney S., Moodie, Zoe, Grove, Doug, Gray, Glenda, Bekker, Linda-Gail, McElrath, M. Juliana, Tomaras, Georgia D., Goepfert, Paul, Kalams, Spyros, Baden, Lindsey R., Lally, Michelle, Dolin, Raphael, Blattner, William, Kalichman, Artur, Figueroa, J. Peter, Pape, Jean, Schechter, Mauro, Defawe, Olivier, De Rosa, Stephen C., Montefiori, David C., Nabel, Gary J., Corey, Lawrence, Keefer, Michael C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152265/ https://www.ncbi.nlm.nih.gov/pubmed/21857901 http://dx.doi.org/10.1371/journal.pone.0021225

Ejemplares similares

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa
por: Jaoko, Walter, et al.
Publicado: (2010)

A multiclade DNA/Ad vaccines for AIDS: the present and next generation
por: Nabel, Gary J
Publicado: (2006)

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
por: Williams, WB, et al.
Publicado: (2012)

P14-03. HIV-specific T-lymphocyte proliferative responses induced by a multigene multiclade HIV-1 DNA/MVA heterologous vaccine in Tanzanian volunteers
por: Aboud, S, et al.
Publicado: (2009)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
por: Bakari, M, et al.
Publicado: (2009)

T-Cell Immune Responses Against Env from CRF12_BF and Subtype B HIV-1 Show High Clade-Specificity that Can Be Overridden by Multiclade Immunizations
por: Mónaco, Daniela C., et al.
Publicado: (2011)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
por: Gray, GE, et al.
Publicado: (2009)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
por: Fong, Youyi, et al.
Publicado: (2018)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa
por: Lazarus, Erica Maxine, et al.
Publicado: (2014)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses
por: Hopkins, Kathryn L., et al.
Publicado: (2014)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
por: Ditse, Zanele, et al.
Publicado: (2020)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

Pregnancy Incidence and Correlates during the HVTN 503 Phambili HIV Vaccine Trial Conducted among South African Women
por: Latka, Mary H., et al.
Publicado: (2012)

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
por: Palli, Rohith, et al.
Publicado: (2020)

Profiles of Human Serum Antibody Responses Elicited by Three Leading HIV Vaccines Focusing on the Induction of Env-Specific Antibodies
por: Vaine, Michael, et al.
Publicado: (2010)

Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults
por: Kalams, Spyros A., et al.
Publicado: (2012)

P19-48. Induction of Ad5 neutralizing antibodies in placebo recipients during the Step Trial is not associated with risk of HIV infection
por: Spies, G, et al.
Publicado: (2009)

Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
por: Koblin, B, et al.
Publicado: (2012)

Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023)

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials
por: Volk, JE, et al.
Publicado: (2012)

P13-05. Factors associated with pregnancy during the HVTN 503/Phambili trial, a phase IIB HIV trial of the Merck Ad-5 multi-clade HIV vaccine
por: Latka, M, et al.
Publicado: (2009)

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
por: deCamp, Allan C., et al.
Publicado: (2017)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
por: Fuchs, Jonathan D., et al.
Publicado: (2015)

2896. Oral PrEP Uptake among HVTN 704/HPTN 085 Participants: Implications for the Future of Biomedical HIV Prevention Trials
por: Cantos, Valeria D, et al.
Publicado: (2023)

P15-15. Advocates' perspectives on community engagement in the HVTN 505
por: Warren, M, et al.
Publicado: (2009)

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
por: Huang, Yunda, et al.
Publicado: (2022)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity
por: Graham, Barney S., et al.
Publicado: (2010)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fim43vsn709p590j8jjroghhm8